Our Piplines

LSB-T06 emerged from LifeSpring Biotech’s macrophage-focused discovery platform designed to pinpoint key regulators of macrophage activation in immunosuppressive tumor microenvironments. LSB-T06 is an intracellular protein largely restricted to myeloid cell populations.

Inhibiting LSB-T06 triggers robust activation of the TLR–MyD88 signaling pathway, driving increased production of pro-inflammatory cytokines such as TNFα, IL-12, and IL-6. This immune activation occurs predominantly within the tumor microenvironment, significantly reducing systemic exposure and offering advantages over conventional systemic TLR–MyD88 agonists.

The LSB-T06 program is currently in the Hit-to-Lead stage, with several high-potency, highly selective compound families advancing in parallel.

LSB-T02 is a newly characterized plasma-membrane glycoprotein primarily expressed on mucosal epithelial cells. Initially identified as an “LSB signal” during a CRISPRa-based tumor screen, the protein is believed to influence both cell adhesion and suppression of myeloid cell activity.

LSB-T02 is notably overexpressed across several major cancer types—including colorectal, gastric, liver, pancreatic, cervical, and testicular tumors—and has been linked to malignant progression in multiple solid cancers. Importantly, its expression patterns correlate with disease trajectory, underscoring its potential biological and therapeutic relevance.